Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Reducing the stigma and discrimination associated with mental illness is becoming an increasingly important focus for research, policy, programming and intervention work. While it has been well established that the healthcare system is one of the key environments in which persons with mental illnesses experience stigma and discrimination there is little published literature on how to build and deliver successful anti-stigma programs in healthcare settings, towards healthcare providers in general, or towards specific types of practitioners. Our paper intends to address this gap by providing a set of theoretical considerations for guiding the design and implementation of anti-stigma interventions in healthcare.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4805707 | PMC |
| http://dx.doi.org/10.1007/s10597-015-9910-4 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Dopamine DR availability after discontinuation of antipsychotic treatment: a [C]raclopride PET study in remitted first-episode psychosis patients.
Psychol Med
September 2025
https://ror.org/03cv38k47University of Groningen, University Medical Centre Groningen, Center for Clinical Neuroscience and Cognition, Groningen, The Netherlands.
Background: After remission of a first-episode psychosis (FEP), antipsychotic discontinuation is associated with an increased risk of relapse compared to maintenance treatment. We studied short and longer-term effects of discontinuation of D receptor (DR) antagonist and partial agonist antipsychotics on striatal dopamine DR availability in FEP patients.
Methods: Remitted FEP patients underwent two [C]raclopride PET scans to measure striatal DR availability: 1 week after antipsychotic discontinuation (n = 16 antagonist users, n = 6 partial agonist users) and after being medication free for 6-8 weeks (n = 8 antagonist users, n = 5 partial agonist users).
Peripheral Inflammation Is Associated With Greater Neuronal Injury and Lower Episodic Memory Among Late Middle-Aged Adults.
J Neurochem
September 2025
Division of Neurogeriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden.
Elucidating the earliest biological mechanisms underlying Alzheimer's disease (AD) is critical for advancing early detection strategies. While amyloid-β (Aβ) and tau pathologies have been central to preclinical AD research, the roles of peripheral biological processes in disease initiation remain underexplored. We investigated patterns of F-MK6240 tau positron emission tomography (PET) and peripheral inflammation across stages defined by Aβ burden and neuronal injury in n = 132 (64.
View Article and Find Full Text PDFToo Much and Too Little Medicine Are Two Sides of the Same Coin.
Australas J Dermatol
September 2025
School of Clinical Medicine (St Vincent's Campus), UNSW Medicine, Australia.
Associations between psychotic experience dimensions and polygenic liability to schizophrenia in a longitudinal birth cohort.
BJPsych Open
September 2025
Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Population Health Sciences, Bristol Medical School, Bristol, UK.
Background: Some psychotic experiences in the general population show associations with higher schizophrenia and other mental health-related polygenic risk scores (PRSs), but studies have not usually included interviewer-rated positive, negative and disorganised dimensions, which show distinct associations in clinical samples.
Aims: To investigate associations of these psychotic experience dimensions primarily with schizophrenia PRS and, secondarily, with other relevant PRSs.
Method: Avon Longitudinal Study of Parents and Children (ALSPAC) birth cohort participants were assessed for positive, negative and disorganised psychotic experience dimensions from interviews, and for self-rated negative symptoms, at 24 years of age.